Cargando…

Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial

BACKGROUND: Dyslipidemia is a risk factor for the progression of chronic kidney disease (CKD). While conventional lipid lowering therapy provides a benefit to CKD management, the effect of statins on eGFR remains unclear. METHODS: A prospective, multi-center, open-labeled, randomized trial. Total of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kimura, Genjiro, Kasahara, Masato, Ueshima, Kenji, Tanaka, Sachiko, Yasuno, Shinji, Fujimoto, Akira, Sato, Toshiya, Imamoto, Miyuki, Kosugi, Shinji, Nakao, Kazuwa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Japan 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486454/ https://www.ncbi.nlm.nih.gov/pubmed/27392909 http://dx.doi.org/10.1007/s10157-016-1304-6

Ejemplares similares

The association between uric acid levels and renal function of CKD patients with hyperlipidemia: a sub-analysis of the ASUCA trial
por: Kuwabara, Yoshihiro, et al.
Publicado: (2019)

Intra-abdominal fat area is a predictor for new onset of individual components of metabolic syndrome: MEtabolic syndRome and abdominaL ObesiTy (MERLOT study)
por: NAKAO, Yoko M., et al.
Publicado: (2012)

Is Pulse Pressure a Predictor of New-Onset Diabetes in High-Risk Hypertensive Patients?: A subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial
por: Yasuno, Shinji, et al.
Publicado: (2010)

Comparison of the Antialbuminuric Effects of L-/N-type and L-type Calcium Channel Blockers in Hypertensive Patients with Diabetes and Microalbuminuria: The Study of Assessment for Kidney Function by Urinary Microalbumin in Randomized (SAKURA) Trial
por: Ando, Katsuayuki, et al.
Publicado: (2013)

Atorvastatin protects endothelium by decreasing asymmetric dimethylarginine in dyslipidemia rats
por: Zheng, Dongdan, et al.
Publicado: (2015)

Synergistic effects of atorvastatin and rosiglitazone on endothelium protection in rats with dyslipidemia
por: Zhang, Wei-Li, et al.
Publicado: (2014)

Efficacy and Safety of Atorvastatin in South Asian Patients with Dyslipidemia: An Open Label Noncomparative Pilot Study
por: Patel, Jeetesh V, et al.
Publicado: (2005)

Effect of Atorvastatin on Growth Differentiation Factor-15 in Patients with Type 2 Diabetes Mellitus and Dyslipidemia
por: Kim, Ji Min, et al.
Publicado: (2016)

To study the effect of high dose Atorvastatin 40 mg versus 80 mg in patients with dyslipidemia
por: Agrawal, Deepak, et al.
Publicado: (2018)

EFFICACY AND SAFETY OF A SINGLE-PILL COMBINATION OF ATORVASTATIN/AMLODIPINE IN PATIENTS WITH ARTERIAL HYPERTENSION AND DYSLIPIDEMIA
por: Naydenov Naydenov, Stefan, et al.
Publicado: (2018)

Effects and potential mechanism of atorvastatin treatment on Lp-PLA2 in rats with dyslipidemia
por: Zheng, Dongdan, et al.
Publicado: (2017)

Atorvastatin-induced pancreatitis
por: Prajapati, Samir, et al.
Publicado: (2010)

Atorvastatin (Lipitor) by MCR
por: Zarganes-Tzitzikas, Tryfon, et al.
Publicado: (2019)

Effect of atorvastatin on glycaemia progression in patients with diabetes: an analysis from the Collaborative Atorvastatin in Diabetes Trial (CARDS)
por: Livingstone, Shona J., et al.
Publicado: (2015)

A comparative evaluation of safety and efficacy of rosuvastatin, simvastatin, and atorvastatin in patients of type 2 diabetes mellitus with dyslipidemia
por: Adsule, Samir Maruti, et al.
Publicado: (2009)

Atorvastatin combined with poly-unsaturated fatty acid confers better improvement of dyslipidemia and endothelium function
por: Song, Xianbing, et al.
Publicado: (2014)

Interaction and potential mechanisms between atorvastatin and voriconazole, agents used to treat dyslipidemia and fungal infections
por: Xun, Tianrong, et al.
Publicado: (2023)

Therapeutic effects of atorvastatin and ezetimibe compared with double-dose atorvastatin in very elderly patients with acute coronary syndrome
por: Liu, Zhi, et al.
Publicado: (2017)

Predictive Significance of Kidney Myeloid-Related Protein 8 Expression in Patients with Obesity- or Type 2 Diabetes-Associated Kidney Diseases
por: Kuwabara, Takashige, et al.
Publicado: (2014)

Atorvastatin and cardiovascular risk in the elderly – patient considerations
por: Acharjee, Subroto, et al.
Publicado: (2008)

Atorvastatin-induced acute pancreatitis
por: Deshpande, Prasanna R., et al.
Publicado: (2011)

Bioenhancing effects of naringin on atorvastatin
por: Sama, Venkatesh, et al.
Publicado: (2019)

Atorvastatin-Induced Refractory Thrombocytopenia
por: Ghuman, Jasmine, et al.
Publicado: (2021)

Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia
por: Kumar, Shoba Sujana, et al.
Publicado: (2009)

Efficacy and Safety of High-Dose Atorvastatin in Moderate-to-High Cardiovascular Risk Postmenopausal Korean Women with Dyslipidemia
por: Moon, Jaecheol, et al.
Publicado: (2020)

Safety of atorvastatin in Asian patients within clinical trials
por: Chan, Juliana C. N., et al.
Publicado: (2016)

Effects of Atorvastatin in Patients with Acute Spinal Cord Injury
por: Aghazadeh, Javad, et al.
Publicado: (2017)

Myopathy in Patients Taking Atorvastatin: A Pilot Study
por: Manoj, K., et al.
Publicado: (2017)

Similar Medication Compliance and Control of Dyslipidemia WithSimvastatin or Atorvastatin in a Staff-Model HMO Medical Clinic
por: Valdez, Connie A., et al.
Publicado: (2005)

The effects of super-flux (high performance) dialyzer on the plasma glycosylated pro-B-type natriuretic peptide (proBNP) and glycosylated N-terminal proBNP in end-stage renal disease patients on dialysis
por: Nakagawa, Yasuaki, et al.
Publicado: (2013)

Atorvastatin solid dispersion for bioavailability enhancement
por: Shamsuddin,, et al.
Publicado: (2016)

Atorvastatin Induced Erythrocytes Membrane Blebbing
por: Rana, Rumaisa Bashir, et al.
Publicado: (2019)

Dissolution Enhancement of Atorvastatin Calcium by Cocrystallization
por: Al-Kazemi, Reham, et al.
Publicado: (2019)

Atorvastatin: DRESS syndrome: case report
Publicado: (2021)

Spectroscopic studies on photodegradation of atorvastatin calcium
por: Oprica, Madalina, et al.
Publicado: (2021)

Atorvastatin: Acute pancreatitis: case report
Publicado: (2021)

Metabolic Alterations Associated with Atorvastatin/Fenofibric Acid Combination in Patients with Atherogenic Dyslipidaemia: A Randomized Trial for Comparison with Escalated-Dose Atorvastatin
por: Han, Ji Soo, et al.
Publicado: (2018)

Tolerability and effectiveness of every-other-day atorvastatin compared to daily atorvastatin in patients with muscle symptoms: A randomized controlled clinical trial
por: Wijekoon, Nirmala, et al.
Publicado: (2020)

Combination Treatment of Rosuvastatin or Atorvastatin, with Regular Exercise Improves Arterial Wall Stiffness in Patients with Coronary Artery Disease
por: Toyama, Kensuke, et al.
Publicado: (2012)

Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes Trial
por: Soedamah-Muthu, Sabita S., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1riug265c3m5lvhio2qriqbt0q